Indication for testing:
Recommended test to confirm a diagnosis of hereditary breast and/or ovarian cancer in individuals with a personal or family history of breast and/or ovarian cancer.
When a relative has a previously identified pathogenic sequence variant, see Familial Mutation, Targeted Sequencing (2001961 
DISEASE OVERVIEW Associated Disorder

BRCA1-and BRCA2-associated HBOC syndrome
Individuals with a pathogenic BRCA1 or BRCA2 variant are at increased risk for breast, ovarian, fallopian, peritoneal, pancreatic, prostate, melanoma, and other cancers.
Etiology
At least 5-10% of all breast cancers and 10-15% of all ovarian cancers are associated with a hereditary cause. 
Inheritance
All genes tested on the HBOC panel are autosomal dominant with the exception of the MUTYH gene, which is autosomal recessive but may also have autosomal dominant risks that are not well defined.
Some genes are associated with autosomal recessive childhood cancer predisposition or other syndromes.
See Genes Tested table for genes included in the panel.
Clinical Sensitivity
Variable, dependent on phenotype/condition BRCA1 and BRCA2 sequencing and deletion/duplication testing alone detects 20-60% of HBOCs, in general (Pruthi, 2010; Meindl, 2011) . >80% of BRCA1 and BRCA2 variants are detectable by sequencing.
10% of BRCA1 and BRCA2 variants are detectable by large deletion/duplication analysis. 
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